News und Analysen
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”)
Sensorion to Attend Two Conferences in June 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis erhält einen Innovationsförderkredit über 1,25 Millionen Euro von Bpifrance
Valbiotis (FR0013254851 – ALVAL, PEA/SME-fähig) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Transgene: Combined General Meeting of May 26, 2021
Regulatory News:
The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 26, 2021) at 10:00 a.m. at the Company's headquarters (400
Valbiotis Granted a €1.25 Million Innovation Support Loan by Bpifrance
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Valbiotis erhält Patent für seinen Wirkstoff TOTUM•63 in China, einem Markt mit großem Potential bei der Vorbeugung von Typ-2-Diabetes und Stoffwechselkrankheiten
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005957/en/
Please replace the release dated May 19, 2021 with
Quantum Genomics Announces the Publication of New Scientific Article in Biomedecine et Pharmacotherapy which further strengthen its Phase III development plan in difficult to treat and resistant hypertension
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to
Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases
Regulatory News:
Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion Publishes Results of Combined General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511006169/en/
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX), a
Sensorion to Attend Three Conferences in May 2021 Including ASGCT to Present a Poster and Co-Chair a Scientific Session
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210502005042/en/
Figure 1. Evolution of BCVA in ND4-LHON patients
Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Regulatory News:
NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
Regulatory News:
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities
Quantum Genomics Secures 3 Million euros Non-dilutive Financing
€1.5 million guaranteed by the French government (PGE) and granted by BNP bank €1.5 million innovation and R&D loan granted by Bpifrance Funding will allow for acceleration of R&D programs
Quantum
Transgene Reports Business Update and End Q1 2021 Financial Position
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business
BOIRON : 2021 fisrt quarter activity
(Unaudited data)
In thousands of euros 2021 2020 Variation at current exchange rates Variation at constant exchange rates France 51,518 72,820 -29.3% -29.3%Quantum Genomics will Present Top-line Results from its QUORUM study of Firibastat in Heart Failure post Myocardial Infarction at the European Society of Cardiology (ESC) Meeting
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and